Navigation Links
Cardiovascular fitness not affected by cancer treatment
Date:5/28/2009

Washington, DC The cardiovascular fitness level of cancer survivors is not affected by many standard cancer therapies, say researchers from Georgetown University Medical Cancer. That is the finding of a new observational study to be presented today at the American College of Sports Medicine in Seattle.

"We know physical activity is a critical component of cancer survivorship, both during and after cancer treatment," says Jennifer LeMoine, PhD, a post-doctoral research fellow with training in exercise physiology at GUMC's Lombardi Comprehensive Cancer Center. "In order to prescribe an exercise program, it's critical that we understand our patient's fitness level and whether or not treatment has had an impact on their cardiovascular health."

For the study, the researchers conducted a chart review of 49 women who attended a physician-directed fitness clinic for cancer survivors, founded and run by Priscilla Furth, MD, the study's co-author. The data included demographics, physical activity levels and cancer treatment type, duration and time since their treatment. Fitness assessments were conducted using a three-minute step test during a clinic visit. The purpose of the study was to access the step test as a way of determining a patient's current cardiovascular fitness level.

LeMoine says, "Often, what people think they are physically capable of doing and what they can actually do are two very different things. Many have a better fitness level than they expect while some find they're not as fit as they thought. The step-test gives us a better idea of their exercise tolerance and cardiovascular-fitness."

All the patients in the study were women and were diverse by age and body mass index. Their cancer diagnoses and treatments varied. Overall, 33 percent of the survivors were sedentary and 67 percent reported being physically active. Thirty-five (71 percent) of the participants completed the step test. Test completion and heart rate recovery were not affected by treatment, BMI, or age.

"What's really exciting to us was that we found that cardiovascular fitness was not affected by the expected culprits -- cancer treatment, type, duration or time since treatment," LeMoine explains. "That isn't to say there aren't side-effects of some treatments that may hinder physical activity, but when it comes to actual cardiovascular fitness as measured in our clinic, many of the standard treatments didn't have a role."

"We've modified an in-clinic cardiovascular assessment tool , the three-minute step test, with the goal of finding a test that can easily and quickly be performed in a physician's office," explains Priscilla A. Furth, MD, a professor of oncology and medicine at Lombardi. "Having this kind of evaluation tool is critical for physicians, like me, who are interested in prescribing physical activity for this population."


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. Health and Advocacy Leaders Mobilize to Bring Attention to Atrial Fibrillation, a Costly and Misunderstood Cardiovascular Disease
2. Study: Women with hard to diagnose chest pain symptoms at higher risk for cardiovascular events
3. The cardiovascular benefits of daily exercise in school children are evident even after 1 year
4. 30-year follow-up study: Tremendous impact of smoking on mortality and cardiovascular disease
5. More evidence for the benefit of exercise in cardiovascular disease -- and even in heart failure
6. The cardiovascular benefits of daily exercise in school children are evident even after one year
7. New Research Demonstrates that Wild Blueberries May Support Cardiovascular Health
8. MedAptus Charge Capture Technology Deployed at Leading Manhattan Cardiovascular Practice
9. SCAI Statement on A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study
10. CorMatrix Cardiovascular to Present on its ECM Technology(TM) at the Annual Advanced Cardiac Techniques in Surgery (ACTS) Symposium in New York, N.Y.
11. VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Finn Mouseson”: ... take precedence in an average life. This mouse sets out on a journey that ... heart. “Finn Mouseson” is the creation of newly published author and illustrator, Melody Gersonde-Mickelson, ...
(Date:9/20/2017)... ... ... “The Financial Favor of God; Second Edition”: a personal and exquisite recipe ... creation of published author, Brooks Rathell. , “We typically hear about the favor of ... financial favor of God. Not only does it exist, but it is meant for ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, ... marketing leader, Denise Flannery, to its strategic advisory and client development team. ... will work with clients across different industries to develop and implement market-justified strategies, ...
(Date:9/19/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted at ...
(Date:9/19/2017)... MD (PRWEB) , ... September 19, 2017 , ... ... the Society of Professional Benefit Administrators (SPBA) hosted “Expanding Your Success” ... for SPBA Members as it focused on best practices for third party administrators ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... Sept. 9, 2017  Eli Lilly and Company (NYSE: ... secondary endpoint data for lasmiditan, an investigational, oral, first-in-class ... statistically significant improvements compared to placebo in the Phase ... at the 18th Congress of the International Headache Society ... "The data presented today demonstrate lasmiditan,s potential to reduce ...
(Date:9/7/2017)... 7, 2017 Caris Life Sciences, a ... the promise of precision medicine, today announced results ... of its molecular profiling approach in guiding therapeutic ... profiling plus (CGP+) with Caris Molecular Intelligence ® ... a molecular level, leading to more therapeutic options ...
Breaking Medicine Technology: